CD33 and acute myeloid leukemia: Though mAb2 strongly stains cancer cells, avoiding healthy hematopoietic stem and progenitor cells (HSPCs) will be critical to avoid the associated toxicities seen with other AML targets (i.e. CD33 and CD123)40.